The Role of Volatile Organic Compounds (VOCs), Airway Mucins and the Microbiome in the Early Prediction of Bronchopulmonary Dysplasia (BPD)

Launched by UNIVERSITY HOSPITAL, ANTWERP · Mar 28, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating important factors related to bronchopulmonary dysplasia (BPD), a common lung problem in very premature babies. The researchers want to find out if certain substances in a baby's breath, called volatile organic compounds (VOCs), can help detect BPD early. They will also look at the types of bacteria in the airways of infants with BPD and how these might be related to the disease. Additionally, the study will explore changes in airway mucins, which are proteins that help protect the lungs. By understanding these connections better, the team hopes to improve early detection and treatment options for BPD.

The trial is open to preterm infants born before 30 weeks of pregnancy, including both those with BPD and those without. To participate, babies must not have serious congenital defects and should be stable according to their doctor. If eligible, families can expect their child to undergo non-invasive testing, including breath samples and assessments of the airway microbiome, all aimed at improving our understanding of BPD and enhancing future care for these vulnerable infants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Born at a gestational age \< 30 weeks
• Exclusion Criteria:
• • Major congenital defect or disorder
• • Patients with an unstable general condition as deemed by the attending neonatologist